{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T14:50:41Z","timestamp":1792507841052,"version":"4.5.0"},"reference-count":25,"publisher":"Society of Nuclear Medicine","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.2967\/jnumed.123.265599","type":"journal-article","created":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T12:50:18Z","timestamp":1686833418000},"page":"1449-1455","source":"Crossref","is-referenced-by-count":121,"title":["Development of FAPI Tetramers to Improve Tumor Uptake and Efficacy of FAPI Radioligand Therapy"],"prefix":"10.2967","volume":"64","author":[{"given":"Yizhen","family":"Pang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianyang","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingxin","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhide","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haojun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2023,6,15]]},"reference":[{"key":"2023091409501487000_64.9.1449.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gde.2009.01.003"},{"key":"2023091409501487000_64.9.1449.2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.87.18.7235"},{"key":"2023091409501487000_64.9.1449.3","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.224469"},{"key":"2023091409501487000_64.9.1449.4","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.227967"},{"key":"2023091409501487000_64.9.1449.5","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1007\/s00259-020-04769-z","article-title":"Comparison of [68Ga]Ga-DOTA-FAPI-04 and [18F] FDG PET\/CT for the diagnosis of primary and metastatic lesions in patients with various types of cancer","volume":"47","author":"Chen","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2023091409501487000_64.9.1449.6","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.245084"},{"key":"2023091409501487000_64.9.1449.7","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.264941"},{"key":"2023091409501487000_64.9.1449.8","doi-asserted-by":"crossref","first-page":"e523","DOI":"10.1097\/RLU.0000000000003810","article-title":"Feasibility and therapeutic potential of 177Lu-fibroblast activation protein inhibitor-46 for patients with relapsed or refractory cancers: a preliminary study","volume":"46","author":"Assadi","year":"2021","journal-title":"Clin Nucl Med."},{"key":"2023091409501487000_64.9.1449.9","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.7150\/thno.69475","article-title":"Fibroblast activation protein-based theranostics in cancer research: a state-of-the-art review","volume":"12","author":"Zhao","year":"2022","journal-title":"Theranostics."},{"key":"2023091409501487000_64.9.1449.10","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.259192"},{"key":"2023091409501487000_64.9.1449.11","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.262533"},{"key":"2023091409501487000_64.9.1449.12","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.263016"},{"key":"2023091409501487000_64.9.1449.13","first-page":"65","article-title":"Novel fibroblast activation protein inhibitor-based targeted theranostics for radioiodine-refractory differentiated thyroid cancer patients: a pilot study","volume":"32","author":"Ballal","year":"2022","journal-title":"Thyroid."},{"key":"2023091409501487000_64.9.1449.14","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.264036"},{"key":"2023091409501487000_64.9.1449.15","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1021\/acs.molpharmaceut.2c00424","article-title":"Development of fibroblast activation protein inhibitor-based dimeric radiotracers with improved tumor retention and antitumor efficacy","volume":"19","author":"Zhao","year":"2022","journal-title":"Mol Pharm."},{"key":"2023091409501487000_64.9.1449.16","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-19-1098"},{"key":"2023091409501487000_64.9.1449.17","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.107.039859"},{"key":"2023091409501487000_64.9.1449.18","doi-asserted-by":"publisher","DOI":"10.1021\/bc900167c"},{"key":"2023091409501487000_64.9.1449.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.nucmedbio.2013.01.002"},{"key":"2023091409501487000_64.9.1449.20","doi-asserted-by":"crossref","first-page":"3930","DOI":"10.1021\/mp500283k","article-title":"PET and SPECT imaging of a radiolabeled minigastrin analogue conjugated with DOTA, NOTA, and NODAGA and labeled with 64Cu, 68Ga, and 111In","volume":"11","author":"Roosenburg","year":"2014","journal-title":"Mol Pharm."},{"key":"2023091409501487000_64.9.1449.21","doi-asserted-by":"publisher","DOI":"10.1021\/bc9000245"},{"key":"2023091409501487000_64.9.1449.22","doi-asserted-by":"crossref","first-page":"5993","DOI":"10.3390\/molecules25245993","article-title":"Preclinical evaluation of the copper-64 labeled GRPR-antagonist RM26 in comparison with the cobalt-55 labeled counterpart for PET-imaging of prostate cancer","volume":"25","author":"Baun","year":"2020","journal-title":"Molecules."},{"key":"2023091409501487000_64.9.1449.23","doi-asserted-by":"crossref","first-page":"8561","DOI":"10.1039\/C8SC01777H","article-title":"Zwitterlation mitigates protein bioactivity loss in\u00a0vitro over PEGylation","volume":"9","author":"Han","year":"2018","journal-title":"Chem Sci."},{"key":"2023091409501487000_64.9.1449.24","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-010-1615-x"},{"key":"2023091409501487000_64.9.1449.25","doi-asserted-by":"crossref","first-page":"422","DOI":"10.7150\/thno.68182","article-title":"Evans blue-modified radiolabeled fibroblast activation protein inhibitor as long-acting cancer therapeutics","volume":"12","author":"Wen","year":"2022","journal-title":"Theranostics."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.123.265599","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T12:52:53Z","timestamp":1694695973000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.123.265599"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,15]]},"references-count":25,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,9,1]]},"published-print":{"date-parts":[[2023,9]]}},"alternative-id":["10.2967\/jnumed.123.265599"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.123.265599","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,15]]}}}